Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0WMMER |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | 022 (CD33) |
|||||
| Organization | CSPC MEGALITH BIOPHARMACEUTICAL CO.,LTD. |
|||||
| Synonyms |
022 (CD33)
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG |
|||||
| Antigen Name | Myeloid cell surface antigen CD33 (CD33) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
QVQLQQPGAEVVKPGASVKMSCKASGYTFTSYYIHWIKQTPGQGLEWVGVIYPGNDDISY
NOKFOGKATLTADKSSTTAYMQLSSLTSEDSAVYYCAREVRLRYFDVWGQGTTVTVSSAS TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST YRVVSVLTVLHQDWLNGKEYKCKVSNKALAASIEKTISKAKGQPREPQVYTLPPSRDELT KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ GNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
SYYIH
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
VIYPGNDDISYNQKFQG
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
EVRLRYFDV
Click to Show/Hide
|
|||||
| Light Chain Sequence |
EIVLTQSPGSLAVSPGERVTMSCKSSQSVFFSSSQKNYLAWYQQIPGQSPRLLIYWASTR
ESGVPDRFTGSGSGTDFTLTISSVQPEDLAIYYCHQYLSSRTFGQGTKLEIKRTVAAPSV FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
KSSQSVFFSSSQKNYLA
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
HQYLSSRT
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
WASTRES
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
wO2024222841A1 ADC59 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
108.30%
|
High CD33 expression (CD33+++) | ||
| Method Description |
Investigated the antitumour effect of 1mg/kg ADC in a CD33high MV-4-11 xenograft NOD SCID mice tumour model, D19.
|
||||
| In Vivo Model | CD33-high MV-4-11 xenograft NOD SCID mice tumour model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
2.486 pM
|
High CD33 expression (CD33+++) | ||
| Method Description |
Cytotoxicity of ADC to MV4-11 cells
|
||||
| In Vitro Model | Childhood acute monocytic leukemia | MV4-11 cells | CVCL_0064 | ||
wO2024222841A1 ADC66 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
6.613 pM
|
High CD33 expression (CD33+++) | ||
| Method Description |
Cytotoxicity of ADC to MV4-11 cells
|
||||
| In Vitro Model | Childhood acute monocytic leukemia | MV4-11 cells | CVCL_0064 | ||